Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1/2 1

Status

Completed 2Unknown 1

Sponsor Class

NIH 2OTHER 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Other hematologic neoplasm 3Myeloid 3Classical hematology 2

Conditions

Leukemia 10Leukemia, Myeloid, Acute 7Congenital Abnormalities 6Glioblastoma 5Lung Neoplasms 4Leukemia, Myelomonocytic, Acute 4Leukemia, Monocytic, Acute 4Leukemia, Megakaryoblastic, Acute 4Leukemia, Erythroblastic, Acute 4Gliosarcoma 4Colorectal Neoplasms 4Central Nervous System Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Wilms Tumor 3Uterine Cervical Neoplasms 3Squamous Intraepithelial Lesions 3Myelodysplastic Syndromes 3Colonic Neoplasms 3Carcinoma, Ovarian Epithelial 3Breast Neoplasms 3Sarcoma 2Rectal Neoplasms 2Precancerous Conditions 2Ovarian Neoplasms 2Oligodendroglioma 2Leukemia, Eosinophilic, Acute 2Leukemia, Basophilic, Acute 2Kidney Neoplasms 2Carcinoma, Intraductal, Noninfiltrating 2Brain Neoplasms 2

Interventions

Cyclophosphamide 211fludarabine phosphate 185Azacitidine 160fludarabine 144Busulfan 140Tacrolimus 120Mycophenolic Acid 112Cytarabine 111Whole-Body Irradiation 107Peripheral Blood Stem Cell Transplantation 99Antilymphocyte Serum 97Melphalan 91Filgrastim 87Cyclosporine 83Decitabine 82Methotrexate 79venetoclax 63Granulocyte Colony-Stimulating Factor 56Radiotherapy 49Stem Cell Transplantation 48Thiotepa 47Cord Blood Stem Cell Transplantation 43Clofarabine 42thymoglobulin 41Specimen Handling 35Etoposide 35Methylprednisolone 34Sirolimus 33Biopsy 30Injections 27

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Myelodysplastic Syndromes × DNA Methylation × Clear all
NCT01165996 2019-03-04

Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome

Case Comprehensive Cancer Center

Phase 1/2 Completed
25 enrolled 13 charts
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Thrombocytopenia, Leukemia, Myelomonocytic, Chronic

NCT00454480 2013-08-26

Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

National Cancer Institute (NCI)

Phase 2/3 Completed
2,000 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Congenital Abnormalities, Anemia, Refractory, with Excess of Blasts, Leukemia, Erythroblastic, Acute, Leukemia, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Basophilic, Acute, Leukemia, Eosinophilic, Acute, Leukemia, Myelomonocytic, Acute

NCT00899327 2009-07-08

Biomarkers in Patients at Risk of Developing Myelodysplastic Syndrome or Other Disorders and in Healthy Participants

National Cancer Institute (NCI)

Unknown
200 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡